Table 3.
Univariate analyses for the categorical variables.
| Characteristics | n | Remission group (%) | Non-remission group (%) | χ2 | P-value |
|---|---|---|---|---|---|
| Sex | 1.327 | 0.249 | |||
| Male | 39 | 25(64.10) | 14(35.90) | ||
| Female | 78 | 58(74.36) | 20(25.64) | ||
| Histological type | 1.584 | 0.208 | |||
| Papillary | 110 | 80(72.73) | 30(27.27) | ||
| Follicular | 7 | 3(42.86) | 4(57.14) | ||
| T stage | 10.146 | 0.017 | |||
| T1 | 43 | 35(81.40) | 8(18.60) | ||
| T2 | 21 | 18(85.71) | 3(14.29) | ||
| T3 | 23 | 14(60.87) | 9(39.13) | ||
| T4 | 30 | 16(53.33) | 14(46.67) | ||
| N stage | 2.525 | 0.283 | |||
| N0 | 25 | 19(76.00) | 6(24.00) | ||
| N1a | 18 | 10(55.56) | 8(44.44) | ||
| N1b | 74 | 54(72.97) | 20(27.03) | ||
| Primary tumor multifocal | 0.294 | 0.587 | |||
| Yes | 89 | 62(69.66) | 27(30.34) | ||
| No | 28 | 21(75.00) | 7(25.00) | ||
| Extrathyroidal invasion | 4.882 | 0.027 | |||
| Yes | 64 | 40(62.50) | 24(37.50) | ||
| No | 53 | 43(81.13) | 10(18.87) | ||
| BRAFV600E mutation | 7.526 | 0.006 | |||
| Positive | 74 | 46(62.16) | 28(37.84) | ||
| Negative | 43 | 37(86.05) | 6(13.95) | ||
| Diagnosis time of metastases | 2.630 | 0.105 | |||
| After RT | 25 | 21(84.00) | 4(16.00) | ||
| Before RT | 92 | 62(67.39) | 30(32.61) | ||
| The diameter of metastatic lesions | 26.358 | 0.000 | |||
| ≤1cm | 73 | 64(87.67) | 9(12.33) | ||
| >1cm | 44 | 19(43.18) | 25(56.82) | ||
| Metastases sites | 7.627 | 0.022 | |||
| Only lung metastases | 64 | 52(81.25) | 12(18.75) | ||
| Only lymphatic metastasis | 24 | 15(62.50) | 9(37.50) | ||
| Multi-site metastasis | 29 | 16(55.17) | 13(44.83) |
T, tumor; N, lymph node. RT, radioiodine therapy.